Table 1.
Value | Long-Term Survival Patients | Short-Term Survival Patients | ||
---|---|---|---|---|
No. of patients | 5 | 31 | ||
Age at treatment, years | Mean | 63 | 61.8 | |
Std error | 2.2 | 1.9 | ||
Minimum | 57 | 35 | ||
Median | 64 | 63 | ||
Maximum | 69 | 81 | ||
p-value | 0.94 | |||
Sex | Female, n (%) | 0 | 11 (35.5%) | |
Male, n (%) | 5 (100%) | 20 (64.5%) | ||
p-value | 0.29 | |||
Sorafenib duration of treatment in months | Mean | 6.2 | 4.2 | |
Std error | 2.4 | 0.8 | ||
Minimum | 2 | 0 | ||
Median | 6 | 4 | ||
Maximum | 15 | 18 | ||
p-value | 0.41 | |||
AFP | Category 1, n (%) | 2 (40%) | 8 (28.6%) | |
Category 2, n (%) | 1 (20%) | 9 (32.1%) | ||
Category 3, n (%) | 2 (40%) | 11(39.3%) | ||
p-value | 1.00 | |||
Response to treatment | CR or PR | 2 (40%) | 2 (6.5%) | |
SD or PD | 3 (60%) | 29 (93.5%) | ||
p-value | 0.084 | |||
Tumor burden | High | 4 (80%) | 22 (75.9%) | |
Low | 1 (20%) | 7 (24.1%) | ||
p-value | 1.00 | |||
IrAE grade 3–4 | Yes | 2 (40%) | 0 (0%) | |
No | 3 (60%) | 31 (100%) | ||
p-value | 0.016 | |||
ECOG | 0 | 2 | 10 | |
1 | 3 | 21 | ||
Liver cirrhosis | Yes | 4 | 24 | |
No | 1 | 7 | ||
Cause of liver disease | Hepatitis B | 1 | 9 | |
Hepatitis C | 3 | 22 | ||
Other | 1 | |||
Child–Pugh score | 5 | 2 | 17 | |
6 | 2 | 10 | ||
7 | 4 | |||
NA | 1 | |||
BCLC | B | 3 | 13 | |
C | 2 | 18 |
Abbreviations: No., number; Std error, standard error; AFP, alpha fetoprotein; IrAE, immune-related adverse event; ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona Clinic Liver Cancer.